Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.

Journal of thrombosis and haemostasis : JTH - 1 Nov 2014

Quade-Lyssy P, Abriss D, Milanov P, Ungerer C, Königs C, Seifried E, Schüttrumpf J

Abstract excerpt

BACKGROUND: FVIII neutralizing antibodies are the main complication of substitution therapy in hemophilia A (HA); auto-antibodies against FVIII causing acquired HA can also occur. Treatment of inhibitor patients remains challenging because prophylactic treatment with existing FVIII bypassing agents, all based on constitutively active coagulation factors, is difficult due to their short half-life. OBJECTIVES: To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dependovirus
Share to Factor IX

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Factor Xa

Share to Gene Transfer Techniques

Share to Hemophilia A

Share to Hemostasis

Share to Thrombin

Source

Identifiers

PMID: 25224783
DOI: 10.1111/jth.12731

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.PMID 25224783Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Coagulation factor VIII: biological basis of emerging hemophilia A therapiesSemantic proximity Read ↗

An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B.Semantic proximity Read ↗

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.Semantic proximity Read ↗

Coagulation Factor IX for Hemophilia B TherapySemantic proximity Read ↗

Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.Semantic proximity Read ↗

An updated interactive database for 1692 genetic variants in coagulation factor IX provides detailed insights into hemophilia B.Semantic proximity Read ↗

Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.Semantic proximity Read ↗

Hemophilia B: Analysis of Mutations in the F9 Gene and Perspectives for the Development of Gene Therapy (A Review)Semantic proximity Read ↗

An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B.Semantic proximity Read ↗

The Molecular Basis of FIX Deficiency in Hemophilia B.Semantic proximity Read ↗

Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.